Cannabinoid Encyclopedia

CBD Migraine Evidence Guide

CBD and Migraine: What Does Research Show?

A source-led answer to the CBD-and-migraine question that separates a CBD-dominant vaporized product from isolated CBD, mixed THC/CBD, oral products, and migraine prevention.

The short answer

What should you know first?

Direct human evidence is currently insufficient to support a broad claim that CBD helps migraine. In one randomized crossover trial, an 11% CBD-dominant vaporized cannabis arm was not superior to placebo for pain relief, pain freedom, or most-bothersome-symptom freedom two hours after acute treatment.

Key differences

Compare the right things

Key distinction

CBD-dominant arm

The trial tested vaporized cannabis flower containing 11% CBD, not isolated or oral CBD.

Key distinction

Mixed THC/CBD arm

The combined-product results belong to that formulation and cannot be credited to CBD alone.

Key distinction

Acute versus preventive use

Two-hour outcomes after one treated attack do not answer whether CBD prevents future migraine attacks.

What studies reported

Results worth understanding

These are study-specific findings, not one result for every CBD product, dose, person, or condition. Open the PubMed links to inspect the original records.

CBD-dominant acute migraine trial

The CBD-dominant arm was not superior for two-hour pain relief

An 11% CBD-dominant vaporized cannabis condition was not superior to placebo for pain relief two hours after treatment. The finding belongs to that acute inhaled formulation. PubMed 41469488

CBD-dominant acute migraine trial

The CBD-dominant arm was not superior for two-hour pain freedom

The same CBD-dominant condition was not superior to placebo for complete pain freedom at two hours. PubMed 41469488

CBD-dominant acute migraine trial

The CBD-dominant arm was not superior for most-bothersome-symptom freedom

The CBD-dominant condition was not superior to placebo for freedom from the most bothersome symptom at two hours. PubMed 41469488

Research context

Read the evidence in context

What the direct trial actually found

The controlled human study enrolled 92 adults and treated 247 migraine attacks in a randomized, double-blind, placebo-controlled crossover design. The CBD-dominant condition used vaporized cannabis flower with an 11% CBD concentration. For that arm, the abstract reported no superiority to placebo on the three named two-hour outcomes: pain relief, pain freedom, and freedom from the participant's most bothersome symptom.

Read next Original PubMed record Open the indexed abstract and trial details.

Why formulation attribution matters

The same trial also tested THC-dominant and combined THC/CBD flower. Those are separate interventions. A result for the combined arm cannot be rewritten as a CBD result, and the CBD-dominant flower result cannot automatically describe purified CBD, an oil, a capsule, or another inhaled product. Concentration, delivered amount, route, and co-occurring compounds remain part of the evidence.

Read next Formulation literacy Keep product composition attached to findings.

What remains unknown

This acute-treatment study does not establish whether isolated CBD, oral CBD, repeated dosing, or a preventive regimen changes migraine frequency, headache days, disability, or longer-term safety. The abstract also does not provide CBD-arm effect estimates for the three null comparisons. The appropriate public conclusion is insufficient evidence, not a treatment recommendation and not proof that every CBD preparation has the same result.

Read next Insufficient evidence Read what this conclusion does and does not mean.

Important limits

What can make the answer change?

  1. 1

    Do not turn one formulation-specific null result into a universal conclusion about every CBD route or product.

  2. 2

    Do not attribute the separate combined THC/CBD arm to CBD alone.

  3. 3

    Do not convert an evidence summary into treatment, dosing, or product advice.

Common questions

Questions people ask

Does CBD help migraine?

Current direct human evidence is insufficient for a broad benefit claim. One controlled trial found its CBD-dominant vaporized arm was not superior to placebo on three named two-hour outcomes. PubMed 41469488

Did the migraine trial test CBD oil?

No. It tested vaporized cannabis flower with an 11% CBD concentration. That result should not be silently transferred to oral oil, capsules, isolated CBD, or other products. PubMed 41469488

What about the combined THC and CBD result?

The combined 6% THC plus 11% CBD arm was a separate mixed intervention. Its result cannot be credited to CBD alone. PubMed 41469488

Does this study answer migraine prevention?

No. It evaluated acute treatment of individual attacks and measured key outcomes two hours after vaporization. PubMed 41469488

{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"Does CBD help migraine?","acceptedAnswer":{"@type":"Answer","text":"Current direct human evidence is insufficient for a broad benefit claim. One controlled trial found its CBD-dominant vaporized arm was not superior to placebo on three named two-hour outcomes."}},{"@type":"Question","name":"Did the migraine trial test CBD oil?","acceptedAnswer":{"@type":"Answer","text":"No. It tested vaporized cannabis flower with an 11% CBD concentration. That result should not be silently transferred to oral oil, capsules, isolated CBD, or other products."}},{"@type":"Question","name":"What about the combined THC and CBD result?","acceptedAnswer":{"@type":"Answer","text":"The combined 6% THC plus 11% CBD arm was a separate mixed intervention. Its result cannot be credited to CBD alone."}},{"@type":"Question","name":"Does this study answer migraine prevention?","acceptedAnswer":{"@type":"Answer","text":"No. It evaluated acute treatment of individual attacks and measured key outcomes two hours after vaporization."}}]}